chrisvoncsefalvay/vaers-outcomes huggingface dataset:
All over body and joint pain; Migraine; Dry mouth; Chills; Fever of 101.5 degrees; All over body and joint pain; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 03Sep2021 at 14:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and allergy to poppy seeds. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included loratadine (CLARITIN) and women's probiotic (unspecified); for unknown indication from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Aug2021 at 14:30 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patient previously received sulfamethoxazole/trimethoprim (BACTRIM) and experienced drug allergy. On 04Sep2021 at 06:00, the patient experienced fever of 101.5 degrees, chills, all over body and joint pain, migraine and dry mouth. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever of 101.5 degrees, chills, all over body and joint pain, migraine and dry mouth were not resolved at the time of the report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Parents noticed infant was not breathing well, then noticed that he had stopped breathing-called 911- underwent prolonged resuscitation without recovery.
Fever x5 days- 102.4 x2 days, 101.3 x1 day, 99.7x 2 days. Severe body aches, debilitating headache
Influenza Vaccine administration (Flucelvax) -05/06/2020 at 3:00 pm. Date adverse event started at May 8, 2020 (palpitation, dizziness) with evaluation for Dr., MD treatment with Metroprolol  (dx Sinus tachycardia and High Blood Pressure).  Evaluation by Cardiologist with treatment Metoprolol Succinate ER 25mg daily.
Sharp burning pain on the side of right breast; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the right arm on 21Mar2021 at 15:45 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included atherosclerosis which was treated and healthy then. The patient did not have any known allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ascorbic acid (VIT C), vitamin d nos (VIT D), rosuvastatin calcium (CRESTOR) and ezetimibe (ZETIA); from an unknown date for unknown indication and unknown if ongoing. On 04Apr2021 at 11:00, two weeks after first shot, the patient experienced sharp burning pain on the side of right breast, same side of vaccination. There were no lumps felt. The patient felt the pain randomly, when the patient laid on her breast, after someone hugged her, when her arm fell across the breast. The pain persisted at the same level for two weeks before lessening but pain albeit much less however was still there. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sharp burning pain on the side of right breast was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
A nurse reported the occurrence of vomiting in an 10 year old female who was vaccinated with hepatitis B vaccine recombinant (Engerix-B) for prophylaxis.  The subject had no relevant medical history, concurrent conditions or concurrent medications.  The subject had no adverse experiences following previous immunizations.  On 04/19/02, the subject received her first injection of Engerix-B (Lot # ENG5156A2).  On 04/21/02, two days post-immunization, the subject developed vomiting and fever.  The subject was seen by her primary physician. The events resolved after an unspecified period of time.  At that time, her primary physician considered the events to be unrelated to Engerix-B administration.  On 05/31/02, the subject received her second injection of Engerix-B (Lot # ENG5288A2).  On 06/02/02, two days post-immunization she again developed vomiting and fever.  The subject did not follow up with her physician and the events resolved.  On the office visit for the third injection of Engerix-B, the vaccine provider decided that the events were related to Engerix-B administration and the Engerix-B immunization series was discontinued.
Patient experienced high fever, hives, shakes, vomiting x 2 days. Patient was treated with Tylenol, Motrin and Benadryl.
muscles aching; light headed; distressed; like her brain is not working; arthritis been magnified; more tired than usual; dizzy; Disorientation; mild tenderness on the injection site; This spontaneous case was reported by a consumer and describes the occurrence of DISORIENTATION (Disorientation), VACCINATION SITE PAIN (mild tenderness on the injection site), MYALGIA (muscles aching), DIZZINESS (light headed) and EMOTIONAL DISTRESS (distressed) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced VACCINATION SITE PAIN (mild tenderness on the injection site). On 10-Mar-2021, the patient experienced DISORIENTATION (Disorientation), MYALGIA (muscles aching), DIZZINESS (light headed), EMOTIONAL DISTRESS (distressed), FEELING ABNORMAL (like her brain is not working), ARTHRITIS (arthritis been magnified), FATIGUE (more tired than usual) and DIZZINESS (dizzy). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, DISORIENTATION (Disorientation), FATIGUE (more tired than usual) and DIZZINESS (dizzy) had not resolved and VACCINATION SITE PAIN (mild tenderness on the injection site), MYALGIA (muscles aching), DIZZINESS (light headed), EMOTIONAL DISTRESS (distressed), FEELING ABNORMAL (like her brain is not working) and ARTHRITIS (arthritis been magnified) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that the patient had received her 1st dose of vaccine on the left non-dominant arm.  No concomitant medication was reported.
Patient developed a rash at site of vaccine administration 1 day after initial Moderna dose. Then she had a generalized urticarial eruption, which was present when I evaluated her as a patient on 4/16/2021. I prescribed topical steroids and encouraged her to submit a Vsafe report.
This spontaneous report was received from a patient of unknown age and gender via a company representative. On an unknown date the patient was vaccinated with PNEUMOVAX23 injection (route, dosage schedule, lot number and expiration date not provided). There were no concomitant medication, nor relevant medical history reported. On an unknown date the patient had tongue very sore and hurt bad. The outcome of the event was unknown. Causality relationship between PENUMOVAX23 and the event was not provided.  Additional information has been requested.
Transiently positive for lupus anticoagulant.  Experienced miscarriage in early January 2021, then received first dose of Moderna vaccine on 2/10/2021, followed by second dose Moderna vaccine on 3/10/2021. Tested positive for lupus anticoagulant on 4/24/2021 as part of work up for recurrent miscarriage (experienced previous miscarriage in July 2020 followed by miscarriage in Jan 2021). Repeat lupus anticoagulant test was negative on 7/24/2021. Suspect initial positive test was either a false positive or transiently induced by vaccine. Alternative cause for recurrent miscarriage has since been identified (Robertsonian translocation).
Lightheaded, nausea, fever, headache, sore throat, terrible body aches, fatigue.
I developed  double vision about 36 hours after 2nd COVID19 vaccine. I saw my ophthalmologist after 2 weeks of symptoms and he diagnosed a Left 6th Cranial Nerve Palsy resulting in diplopia.
COVID ARM"; Bruising; Redness; Rash; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (COVID ARM"), CONTUSION (Bruising), VACCINATION SITE ERYTHEMA (Redness) and RASH (Rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (COVID ARM"), CONTUSION (Bruising), VACCINATION SITE ERYTHEMA (Redness) and RASH (Rash). At the time of the report, PAIN IN EXTREMITY (COVID ARM"), CONTUSION (Bruising), VACCINATION SITE ERYTHEMA (Redness) and RASH (Rash) outcome was unknown.            Concomitant information use was not reported.  Treatment information was not provided.   Reporter did not allow further contact
he started displaying OCD symptoms that had previously resolved; he started displaying OCD symptoms that had previously resolved; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 12 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 18Dec2021 (Batch/Lot number: unknown) at the age of 12 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Autism" (ongoing), notes: Verbatim: Autism, Diagnosed at 3 years old.; "OCD" (unspecified if ongoing), notes: They had gotten rid of it years ago with therapy and he started doing it again. There were no concomitant medications.  The following information was reported: OBSESSIVE-COMPULSIVE DISORDER (non-serious), DISEASE PROGRESSION (non-serious) all with onset 27Dec2021, outcome "not recovered" and all described as "he started displaying OCD symptoms that had previously resolved".  Additional information: Mother, calling on behalf of son, aged 12, received his first dose of the adult formulation of the Pfizer BioNTech Covid 19 vaccine on 18Dec2021.Her son has autism.Two days after receiving the vaccine he started displaying OCD symptoms that had previously resolved.She stated for example that during their walks he has started backstepping. It took approximately 2 hours to complete a 45 minute walk.He is still displaying symptoms of OCD a little bit. patient (reporter son) that: Updated information: Patient history: Autism (From: Unspecified To: Ongoing), Additional Information for Other Conditions: Diagnosed at 3 years old. She reported that on Monday, he started to do OCD stuff that he had previously gotten rid of. He was back stepping when they went for a walk at the park and started doing that again. They had gotten rid of it years ago with therapy and he started doing it again. She said that she does not know of it is temporary, but she is praying to God it was not permanent. She said that she was just stating it because people with autism have slightly different chemistry and thinks they are more susceptible to have stuff happen.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Information has been received from a registered nurse concerning a 6 year old female with asthma and drug hypersensitivity to ZITHROMAX who on 21-DEC-2009 was vaccinated intramuscularly with the fourth 0.5 mL dose of PNEUMOVAX 23 (LOT# 664000/0621Y). There was no concomitant medication. The patient was received the first dose of PNEUMOVAX 23 on 01-DEC-2003. On 22-DEC-2009 the patient experienced local reaction in the right deltoid area. The patient was seen in an office and was given BENADRYL. The lab was not performed. At this time of reporting, the patient was recovering. Additional information has been requested.
Patient received first shot on 2/16/21.  He called pharmacy on 2/26/21 to report that he experienced bruising at the injection site which has persisted since receiving the shot (approximately 10 days).  The bruise is about the size of a quarter and is not painful.
Henoch Schonlein Purpura/IgA Vasculitis, with purpuric rash, abdominal pain, diarrhea  1 week post vaccination  IV solumedrol followed by 8 week prednisone taper, rapid improvement with steroids after colonoscopy
A nurse reported that a 3 month old male received Prevnar, IPV (Aventis Pasteur SA), Comvax (Merck) and Tripedia (Aventis Pasteur, Inc) vaccines on 6/27/00 and subsequently, developed a fever.
patient phoned today claiming to have had temporary paralysis from approximately 6pm (07/29) to 230am (07/30). she claims to be fine now.
My healthy 18-year old son had his first dose of Pfizer, and within a few minutes he felt dizzy. His heart rate was also rapid. He didn't think much of it, but the dizziness persisted and so they had him lay down with feet up. After about 20 minutes, he began to vigorously shake (rigors I believe is what it is called.) He felt numb in both arms and also his tongue and mouth. We had 3 nurses attending to him, and after about 30 minutes they decided to send him to the ER for evaluation since the very strong shaking and other symptoms were worsening. The shaking, dizziness, numbness all subsided after about an hour. He was given a Zyrtec upon first symptoms about 15 minutes after dose. The ER doc doesn't believe it was an allergic reaction but potentially a strong vasovagal response and immune response. He felt tired after but was completely fine 2 hours later. We were discharged from the ER a few hours later after evaluation. Vitals were in normal range including blood sugar, blood pressure and oxygen. He was fully hydrated prior and had a turkey sandwich and orange prior to coming so was not low on food either. The shaking was very extreme and concerning. It has been almost 24 hours and he is feeling fine other than a sore arm.
side effects; This case was reported by a consumer via call center representative and described the occurrence of adverse event in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced adverse event. On an unknown date, the outcome of the adverse event was not recovered/not resolved.   It was unknown if the reporter considered the adverse event to be related to Shingrix.  Additional information received were as follows: This case was reported by the patient's husband. The age at vaccination was not reported. The patient experienced all of the side effects of her second shingles shot. The reporter asked if could she take anything to lessen them.
The patient hospitalized due to COVID-19 7/15/2022  7/27/2022. Medications to treat symptoms included folic acid 1mg daily, thiamine 100mg PO daily, ascorbic acid 1000mg PO daily, vitamin D 25mcg PO daily and zinc sulfate 150mg PO daily.
Photo dermatitis face , arms and right hand. Pruritic. Saw dermatologist. He thought possible reaction to HCTZ and sun. HCTZ D/c'd. Seen at Dr office 4/15/10 and 5/10/10. Rash slowly improving. Non pruritic now. Using creams prescribed by dermatologist. Has f/u visit with us about 5/24/10.
large (6x7cm) area of induration & 7x8 cm warmth over anterior thighs; lt thigh w/vesiculations;
cervicalgia, headache: persistent for 12 days. Taking Aleve 2 tabs daily, using heating pad to neck
Gave MCV4 in Rt arm. Pt had a red 4in by 4in area raised with some temp in area. Drew line around raised area & informed mother if get worse go to ER. Also informed to take TYLENOL for pain et BENADRYL for reaction.
generalized urticaria, medical attention needed, treatment with oral antihistamine, ongoing as of today.
Patient came in for first COVID dose. Patient reports that with vaccines and labs he gets dizzy. After the vaccine he was waiting 15 minutes and got dizzy. We gave him alcohol and he got better little by little. It was around 30 minutes. He refused to call 911.
Elevated heart beat, feeling dizzy and woozy, numbness/tingling in arms and legs, muscle tightness on shoulder, discomfort down spine
Oxygen saturation decreased; This is a spontaneous report received from contactable reporter (Consumer or other non HCP). The reporter is the patient. Other Case identifier: NVSC2022US207878_OS.  A 72-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: COVID-19 vaccine (Primary immunisation series completed, Unknown manufacturer), for COVID-19 immunization. The following information was reported: OXYGEN SATURATION DECREASED (non-serious), outcome "unknown". Relevant laboratory tests and procedures are available in the appropriate section.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
This spontaneous report was received from a physician via company representatives referring to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not provided. On 29-OCT-2014, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 0.5 mL (Lot # K007822, expiration date 15-AUG-2015) single dose, route and anatomical location were not provided. There was no concomitant medication provided. No adverse effects were reported. On an unknown date, the PNEUMOVAX had a temperature excursion for 696 hours, the lowest recorded temperature was 20 degrees F. The vaccine status was reported as "in excursion", the storage criteria and the vaccine excursion were reported as "refrigerator (R)". There was no product quality complaint involved. This is one of several cases received from the same reporter. Additional information has been requested.
3 inch long x 1 inch wide oval shaped raised red itchy area a round left deltoid where flu shot given. Reports achy joints, particularly hips, fatigue, irritability. Did not seek medical attention, used Motrin PRN. Has recovered.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 50-year-old female patient (not pregnant) received BNT162b2 (BNT162B2 NOS), on 30Sep2022 as dose number unknown, single (Batch/Lot number: unknown) at the age of 49 years for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Paxlovid from 28Apr2023 to 03May2023.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Menstruation commenced within less than 24 hours following booster shot causing disruption in menstrual cycle.  Bleeding and flow were heavier than normal, as well as, cramping in abdomen/ovary area.
Pt died of SIDS on 1/29/01, in the afternoon. She had no preceding symptoms was breast fed about 1 1/2 hour before the event where she was found dead in a crib. Pathologist's autopsy findings consistent with SIDS.
SEVERE HEAD ACHE (MIGRAINE) LASTING FOR 2 WEEKS WITOUT A BREAK.  REQUIRED PHYSICIAN EVALUATION TO RULE OUT OTHER FACTORS.  PHYSICIAN DETERMINED IT WAS THE VACCINE.  THE MIGRAINE SUBSIDED WITHIN 14 DAYS.
the area had been itching; pain; swelling; hardness; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (swelling), INDURATION (hardness), PRURITUS (the area had been itching) and PAIN (pain) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A, 016B21A and 045(or S)J21A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SWELLING (swelling), INDURATION (hardness), PRURITUS (the area had been itching) and PAIN (pain). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, SWELLING (swelling), INDURATION (hardness) and PAIN (pain) had resolved and PRURITUS (the area had been itching) outcome was unknown.            No concomitant medications provided. Treatment included ice, pain medications and observing.
started having severe cramping with menstral cycles . never had cramps before first started 4/21/2021 has been in the  clinic multiple times and has also missed school at least 4 days over the last 6 months